Rapid Dose Therapeutics Submits QuickStrip Nicotine Oral Film for Health Canada Approval
Key Insights
Rapid Dose Therapeutics (search) has submitted a product application to Health Canada for approval of its QuickStrip Nicotine products in four dose strengths (1-4 mg), marking a significant regulatory milestone for the innovative oral nicotine delivery system.
The fast-dissolving oral thin film technology delivers nicotine through oral mucosa (search) and is designed to mimic cigarette nicotine absorption without harmful combustion byproducts, offering a safer alternative for smokers.
The company has conducted a pharmacokinetic clinical trial comparing QuickStrip Nicotine to traditional cigarettes and worked with a global cigarette manufacturer over 30 months to optimize the product.
Rapid Dose Therapeutics (search) Corp. (CSE: DOSE) has submitted a product application to Health Canada for approval of its QuickStrip Nicotine products, marking a significant regulatory milestone for the Canadian biotechnology company's innovative oral nicotine delivery system. The submission covers four dose strengths—1 mg, 2 mg, 3 mg, and 4 mg formats—developed as a safer alternative to smoking.
Novel Oral Film Technology Targets Harm Reduction
QuickStrip is a fast-dissolving oral thin film that delivers active ingredients directly through the oral mucosa (search). The company's NicStrip product line leverages this platform to provide nicotine in a controlled, smoke-free format aimed at helping smokers reduce or quit smoking altogether.
"We believe this submission represents a critical advancement in our mission to support harm reduction for smokers," said Mark Upsdell, CEO of Rapid Dose Therapeutics (search). "With millions of Canadians seeking safer nicotine alternatives, QuickStrip offers a convenient, discreet, and non-combustible option. Our goal is to empower individuals with effective tools to reduce the health risks associated with smoking."
The nicotine products are currently undergoing a pharmacokinetic (PK) clinical trial, comparing QuickStrip Nicotine to traditional combustible cigarettes to evaluate absorption and efficacy. The PK study is being conducted under Good Clinical Practice (GCP) guidelines and is designed to gather detailed data on the bioavailability of nicotine delivered via the QuickStrip platform compared to inhaled nicotine from cigarettes.
Strategic Partnership and Patent Protection
Over the past 30 months, RDT has worked closely with a leading global cigarette manufacturer to refine the QuickStrip Nicotine product in preparation for launch. This strategic partnership has enabled extensive research and development toward product optimization, laying the groundwork for regulatory submission and commercialization.
RDT and its production partner Aavishkar (search) have filed two international patent applications under the Patent Cooperation Treaty (PCT), covering advancements in nicotine delivery, film formulation, and controlled-release technology.
"Our QuickStrip delivery system is designed to mimic the nicotine absorption curve of a cigarette without the harmful byproducts of combustion," said Jason Lewis, Senior Vice President of RDT. "It provides rapid onset, consistent dosing, and eliminates second-hand smoke—critical attributes for any successful smoking cessation (search) or harm reduction strategy."
Personalized Dosing and Market Strategy
The product is intended for use by adult smokers seeking to reduce or quit tobacco use (search). With multiple dose strengths ranging from 1 mg to 4 mg, QuickStrip Nicotine allows users to personalize their nicotine intake and taper use over time, supporting individualized usage plans.
Upon regulatory approval, RDT plans to launch the product across Canada and expand distribution through its commercial partnerships, including potential licensing in other global markets.
Market Opportunity and Regulatory Context
This represents RDT's second attempt at Health Canada approval, following a previous nicotine product application submitted in 2019 that could not be completed due to the COVID-19 pandemic.
The Canadian nicotine pouches market was valued at USD 112.2 million in 2024, with projected annual growth of 4.7% through 2030, driven by increased adoption of discreet, smoke-free alternatives and a growing public health focus on harm reduction, according to Grand View Research.
The initiative aligns with the Government of Canada's Tobacco Strategy (CTS), which aims to reduce tobacco use (search) to less than 5% by 2035, and supports the World Health Organization's goal of reducing adult smoking prevalence by 30% by 2030 as part of the WHO Framework Convention on Tobacco Control (FCTC).
"Today's announcement underscores our commitment to innovation and public health," added Lewis. "We're not just developing a product—we're contributing to a movement toward safer alternatives for nicotine users."